Skip to content

Investors Overview

Esperion is a pharmaceutical company passionately committed to developing and commercializing non-statin, once-daily, oral therapies to lower elevated low-density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid is being developed as a once-daily, oral inhibitor of ATP Citrate Lyase (ACL), and is designed to bring a targeted mechanism of action to address patients’ unmet medical needs.

Esperion has been a publicly traded company since 2013 and is listed on the NASDAQ Global Select Market under the symbol ESPR.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Date Title and Summary
Toggle Summary Esperion to Participate in Two Upcoming Virtual Investor Conferences
ANN ARBOR, Mich., May 06, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that members of Esperion management will participate in two upcoming virtual conferences during the month of May. Event: Bank of America 2021 Healthcare Conference Date: May 13, 2021 Format: Presentation &
Toggle Summary ESPERION Reports First Quarter 2021 Financial Results and Provides Company Update
– U.S. Product Revenue of $6.4 Million, Growing Demand Offset by Lower Net Price – – Prescriptions Grew 46% Sequentially; More Than 35,000 Patients now on NEXLETOL ® (bempedoic acid) Tablets and NEXLIZET ® (bempedoic acid and ezetimibe) Tablets – – Secured Major Medicare Part D Contract Covering
Toggle Summary Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., April 28, 2021 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on April 23, 2021, the Compensation Committee of Esperion’s Board of Directors granted 21 new employees 50,991 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan.
Toggle Summary Esperion Announces Publication of Rationale and Design of Landmark CLEAR Cardiovascular Outcomes Trial Evaluating NEXLETOL® (bempedoic acid) Tablet in American Heart Journal
– First-of-its-kind outcomes trial designed to assess cardiovascular risk reduction in patients with documented intolerance to statin therapy – – Nearly half of trial participants are women, a significantly higher proportion than have been included in any other previous cardiovascular outcomes
Toggle Summary Esperion Announces Publication of Rationale and Design of Landmark CLEAR Cardiovascular Outcomes Trial Evaluating NEXLETOL® (bempedoic acid) Tablet in American Heart Journal
– First-of-its-kind outcomes trial designed to assess cardiovascular risk reduction in patients with documented intolerance to statin therapy – – Nearly half of trial participants are women, a significantly higher proportion than have been included in any other previous cardiovascular outcomes